{"id":652349,"date":"2023-05-22T17:02:02","date_gmt":"2023-05-22T17:02:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=652349"},"modified":"2023-05-22T17:02:02","modified_gmt":"2023-05-22T17:02:02","slug":"acute-coronary-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032key-companies-regeneron-sanofi-dalcor-pharmaceutical","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-coronary-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032key-companies-regeneron-sanofi-dalcor-pharmaceutical_652349.html","title":{"rendered":"Acute Coronary Syndrome Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)|Key Companies &#8211; Regeneron, Sanofi, DalCor Pharmaceutical"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Coronary Syndrome Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)|Key Companies - Regeneron, Sanofi, DalCor Pharmaceutical\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Acute Coronary Syndrome Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032)|Key Companies - Regeneron, Sanofi, DalCor Pharmaceutical\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cAcute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast \u2013 2032\u201d report delivers an in-depth understanding of the ACS, historical and forecasted epidemiology as well as the acute coronary syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-coronary-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Acute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast &ndash; 2032<\/a><\/strong>&rdquo; report delivers an in-depth understanding of the ACS, historical and forecasted epidemiology as well as the acute coronary syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Coronary Syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Acute coronary syndrome (ACS) is a syndrome (a set of signs and symptoms) due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies. The most common symptom is centrally located pressure-like chest pain, often radiating to the left shoulder or angle of the jaw, and associated with nausea and sweating. Many people with acute coronary syndromes present with symptoms other than chest pain, particularly women, older people, and people with diabetes mellitus.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/48f7ee318e5537d995dd5e19e9769e11.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Coronary Syndrome Epidemiology Insights<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The annual incidence of Acute Coronary Syndrome was 22.6 per 10000 of people (34.0 per 10000 men and 10.9 per 10,000 women).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Click here to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-coronary-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Acute Coronary Syndrome Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Report Covers the Acute Coronary Syndrome Epidemiology Segmented by:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome&nbsp; incident cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome prevalent cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome&nbsp; treated cases&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome diagnosed cases&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Coronary Syndrome Market Outlook&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Acute Coronary Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted acute coronary syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. This segment gives a thorough detail of the acute coronary syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">According to DelveInsight, the acute coronary syndrome market in the 7MM is expected to witness a major change in the study period 2019&ndash;2032.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Companies Working in the Acute Coronary Syndrome Market<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Regeneron,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sanofi,&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DalCor Pharmaceutical&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CSL Behring<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Acute Coronary Syndrome Therapies Covered and Analyzed in the Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Milvexian<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Clopidogrel<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Prasugrel<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Apixaban<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-coronary-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Key Companies and Emerging Therapies in the&nbsp; Acute Coronary Syndrome Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong>&nbsp;<\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Key Insights&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome &nbsp; Introduction&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Executive Summary of&nbsp; Acute Coronary Syndrome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disease Background and Overview<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Epidemiology and patient population<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome &nbsp; Emerging Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Acute Coronary Syndrome &nbsp; Market Outlook<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Access and Reimbursement of Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Drivers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Market Barriers&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Appendix<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Report Methodology<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;DelveInsight Capabilities<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">&nbsp;Disclaimer<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Learn about the detailed offerings of the report @&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-coronary-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=dpr\">Acute Coronary Syndrome Market Outlook. <\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Adya Kaul<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-coronary-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032key-companies-regeneron-sanofi-dalcor-pharmaceutical\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/due-diligence-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-coronary-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032key-companies-regeneron-sanofi-dalcor-pharmaceutical\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cAcute Coronary Syndrome Market Insights, Epidemiology, and Market Forecast \u2013 2032\u201d report delivers an in-depth understanding of the ACS, historical and forecasted epidemiology as well as the acute coronary syndrome market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-coronary-syndrome-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20222032key-companies-regeneron-sanofi-dalcor-pharmaceutical_652349.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,417,403,404],"tags":[],"class_list":["post-652349","post","type-post","status-publish","format-standard","hentry","category-Business","category-Marketing-Sales","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/652349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=652349"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/652349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=652349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=652349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=652349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}